EDMONTON, Feb. 18 /CNW/ - Isotechnika Pharma Inc. (Toronto:ISA.TO) is pleased to announce that Dr. Peter Wijngaard, Vice President, Innovation Leader, Research & Development at The Medicines Company, and Dr. Heung-Joon Yang, President, Global Network Services, Inc. have today joined the Board of Directors.
Isotechnika's President & CEO, Dr. Robert Foster commented, "We are excited to welcome these two highly qualified individuals to our Board. They both have a strong depth of relevant experience that can help Isotechnika as we move into Phase 3 for the prevention of kidney transplant rejection and progress our corporate development activities."
Dr. Wijngaard holds a Ph.D. in Immunology from Utrecht University, The Netherlands. Dr. Wijngaard formerly worked for F. Hoffmann-La Roche Ltd. (Basel, Switzerland.) as the Life Cycle Leader Transplantation for voclosporin, Cellcept, Zenapax, and DAC HYP. Dr. Wijngaard's past experience with the development of voclosporin in conjunction with his pharmaceutical industry background will be very beneficial to the Company.
Dr. Yang holds a Ph.D. in Bioengineering from University of Washington (Seattle, Washington, USA) and was the former CEO of LG Life Sciences, Ltd. Dr. Yang has a great deal of experience with cyclosporine analogues and has an in depth understanding of the Company's lead compound, voclosporin.
Both Dr. Wijngaard and Dr. Yang will serve on the Board's Audit Committee. To facilitate the appointment of the new members, Mr. Franklin Berger and Dr. Jurgen Engel have officially agreed to step down from the Company's Board of Directors effective immediately. The Company and the Board thank them both for their service as Directors.
Didn't need much of a news to move upward............imagine if it was of any substance what it would do.
But by the way...seems like things keep on moving foward.